(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 3.04% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Gilead Sciences's revenue in 2025 is $28,863,000,000.On average, 9 Wall Street analysts forecast GILD's revenue for 2025 to be $35,673,126,868,199, with the lowest GILD revenue forecast at $35,466,760,825,157, and the highest GILD revenue forecast at $36,265,063,733,932. On average, 9 Wall Street analysts forecast GILD's revenue for 2026 to be $37,071,086,943,338, with the lowest GILD revenue forecast at $36,261,341,313,184, and the highest GILD revenue forecast at $38,425,308,574,688.
In 2027, GILD is forecast to generate $39,346,209,410,798 in revenue, with the lowest revenue forecast at $38,091,531,514,284 and the highest revenue forecast at $41,121,582,003,156.